The NCT03433469 study included a total of 13 patients with EGFR-mutated stage I-IIIA resectable NSCLC who received 1-2 cycles (28 days/cycle) of osimertinib followed by surgery (Blakely. Here, EGFR is linked to non-small cell lung carcinoma.